"Eculizumab" Pronounce,Meaning And Examples

"Eculizumab" Meaning

Eculizumab is a medication that is used to treat certain types of autoimmune hemolytic anemia, thrombotic thrombocytopenic purpura, and atypical hemolytic-uremic syndrome. It works by blocking the action of a protein called complement 5, which is involved in the activation of the immune system and the destruction of red blood cells. By blocking this protein, eculizumab helps to prevent the immune system from attacking and destroying red blood cells, which can help to reduce the severity of symptoms and improve quality of life for patients with these conditions.

"Eculizumab" Examples

Eculizumab

Eculizumab is a humanized monoclonal antibody used to treat certain autoimmune disorders and blood disorders. Here are five examples of its usage:

Example 1: Eculizumab is used to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disorder characterized by the production of abnormal red blood cells. [1]

Eculizumab was administered to the patient to prevent further destruction of red blood cells.

Example 2: Eculizumab has been shown to be effective in reducing the risk of kidney damage in patients with atypical hemolytic uremic syndrome (aHUS), a rare blood disorder. [2]

The doctor prescribed eculizumab to the patient to prevent kidney failure.

Example 3: Eculizumab is used to treat patients with generalized myasthenia gravis (gMG), an autoimmune disorder that affects the nerves and muscles. [3]

The patient was administered eculizumab to reduce the severity of muscle weakness.

Example 4: Research has been conducted to evaluate the efficacy of eculizumab in treating patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP), a rare blood disorder. [4]

The study found that eculizumab significantly reduced the risk of relapse in patients with iTTP.

Example 5: Eculizumab has been approved for use in certain countries to treat patients with neuromyelitis optica (NMO), an autoimmune disorder that affects the central nervous system. [5]

The patient was prescribed eculizumab to treat their NMO and reduce the risk of relapse.

References:

[1] National Organization for Rare Disorders. (n.d.). Paroxysmal Nocturnal Hemoglobinuria. Retrieved from

[2] United States Food and Drug Administration. (2017). Soliris. Retrieved from

[3] National Multiple Sclerosis Society. (n.d.). Generalized Myasthenia Gravis. Retrieved from